Tiziana Life Sciences plc TLSA 深 滬
已收盤 12-24 16:00:00 美东时间
1.53
+0.070
+4.79%
華盛通- 最 高1.56
- 今 開1.50
- 成交量 21.16万股
- 最 低 1.46
- 昨 收 1.46
- 總市值 1.79亿
- 52周最高 2.60
- 市盈率 靜 --
- 換手率 0.18%
- 52周最低 0.6302
- 委 比 -73.73%
- 總股本 1.17亿
- 歷史最高 12.15
- 量 比 0.71
- 振 幅 6.85%
- 歷史最低 0.41
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tiziana Life Sciences withdraws proposed public offering
Tiziana Life Sciences (TLSA) announced on Monday the withdrawal of the proposed public offering of common shares due to market conditions. Tiziana Life Sciences (TLSA) shares were up 4% in premarket ...
12-15 21:15
Tiziana Life Sciences Begins Enrollment In Phase 2 Alzheimer's Trial Of Intranasal Foralumab, Plans First Dosing Next Week As New PET Data Shows Persistent Neuroinflammation Despite Leqembi Treatment
First Patient Expected to be Dosed Next Week with Intranasal ForalumabPET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi® (Lecanemab) Anti-Amyloid TherapyBOSTON, Dec. 12,
12-13 03:12
Tiziana Life Sciences' Phase 2 Clinical Trial Evaluating Intranasal Foralumab In ALS Patients Accepted For Inclusion In ALS MyMatch Program
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal
11-25 21:33
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
Tiziana Life Sciences announced that its senior leadership team will present at the Jefferies London Healthcare Conference on November 19, 2025. The presentation will focus on the Company’s innovative pipeline, particularly its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody for neurodegenerative diseases. Foralumab has shown promise in treating conditions like non-active secondary progressive multiple sclerosis (...
11-13 13:30
Elon Musk Says Tesla, xAI Are 'Trending Towards Convergence' In Some Ways
Elon Musk's companies could potentially merge in the future as he continues to integrate AI into his ventures.
11-11 12:21
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
Aquestive Therapeutics announced key leadership changes to support the FDA-approved launch of Anaphylm™ and expand its pipeline. Matthew Davis, M.D., joins as Chief Development Officer, Gary Slatko, M.D., M.B.A., becomes interim Chief Medical Officer, and Peter Boyd, M.B.A., is promoted to Chief People Officer. These strategic moves aim to accelerate product development and commercialization efforts, particularly for Anaphylm™, a first-of-its-kin...
11-04 12:00
Tiziana Life Sciences To Present At BIO-Europe 2025, Highlighting Nasal Delivery Platform And Lead Candidate, Intranasal Foralumab, Fully Human Anti-CD3 Monoclonal Antibody In Clinical Development
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,
10-29 19:25
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
Tiziana Life Sciences will present at BIO-Europe 2025, showcasing its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The event, held in Vienna from November 3-5, 2025, will allow Tiziana to engage with industry leaders and investors. The Company's presentation will focus on its innovative nasal delivery platform and the potential of intranasal foralumab to address neuroinflammatory and neurodegenerative diseases...
10-29 11:00
Tiziana Life Sciences Reports Interim Results and Expands U.S. Presence
Tiziana Life Sciences ( ($TLSA) ) has issued an update. On October 3, 2025, Tiz...
10-04 05:04
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
Tiziana Life Sciences announced plans to advance TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody targeting both membrane-bound and soluble forms of IL-6R, while continuing to develop its lead intranasal foralumab program. TZLS-501 inhibits IL-6R signaling and reduces IL-6 cytokines, potentially treating inflammation, lung damage, and fibrosis. The company aims to explore non-dilutive funding for TZLS-501 without diverting resources...
09-25 12:30
